MANAGING COMPLEXITY, DELIVERING VALUE



DVCMN webinar

21st August, 2023





Stevanato Group Speakers




Mr. Riccardo Prete

Product Manager Vials Platform

riccardo.prete@stevanatogroup.com

Riccardo Luigi Prete - Linkedin





Mrs. Flavia Batista **Technical Account Management** Specialist

flavia.batista@stevanatogroup.com



+39 348 5384387

Flavia Batista - Linkedin

- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill[®] Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish Process
- Q&A




- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill[®] Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish Process
- Q&A



Stevanato Group at a glance

What we proudly do



Unique combination of integrated capabilities addresses pharmaceutical customer needs through developmental, clinical and commercial phases

Reduced Time to Market


Reduced Supply
Chain Risk

Reduced Total Cost of Ownership

Consistent Quality

70 years of Expansion, Acquisition, Integration

The story we can tell



Stevanato Group Today, 70+ Countries Served


Our present

16 sites

countries

3 sites

investments underway for EZ-fill® / Engineering







ANALYTICAL AND **TESTING SERVICES**

SOURCE: SG INTERNAL DATA

- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill® Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish
 Process
- Q&A



New Trends are Driving Pharmaceutical Industry



Challenging Trends for Developing Countries

Market Trends

Cost Explosion in Manufacturing



Growth in Emerging Markets



Increasing Regulatory Quality & Compliance



Pharmaceuticals Needs for Fill & Finish



NEED TO REDUCE TOTAL COST OF OWNERSHIP (TCO)



REDUCE TIME TO MARKET



NEED TO INCREASE QUALITY



REDUCE COMPLEXITY



NEED TO INCREASE FLEXIBILITY

COVID-19 Pandemic highlighted the major need to access to infrastructures...

"[..] In terms of vaccine manufacturing capacity and efficiencies, considerations for facility sharing of fill and finish activities are in place and so is the provision of technical guidance on personnel competency improvement and personnel's understanding of regulation related to GMP"

Vaccine manufacturing workshop for South-East Asia and the West Pacific regions: meeting report, 21-22 February 2022

"[..] The Latin America and Caribbean (LAC) region relies heavily on imported COVID-19 vaccines [...], having the second lowest level of domestic supply after Africa."

Expanding Emergency Vaccine Manufacturing Capacity in Latin America and the Caribbean

"[..] support from development financial institutions together with the private sector is crucial in supporting Africa's industrial and sustainable development and countries need to be supported to expand their fiscal space during the ongoing pandemic. [..] development partners need to actively promote human resource capacity and knowledge for the pharmaceutical manufacturing sector which requires highly skilled sonnel."

Strengthening Africa's pharmaceutical industry: learning the lessons from COVID-19 | UNIDO

"[..] Clearly, the cost of setting up production would make the products locally produced in Africa more expensive than those imported from existing suppliers.

But sustainable supply for years to come is worth the shortterm cost."

<u>Scientists call on AU leaders to prioritise mRNA vaccine technology | Nation</u>

Key importance in Developing Countries to <u>develop</u> and strengthen <u>local Capacity</u> and related <u>capabilities</u> in order to ensure <u>access to vaccination</u>

...which requires Pharmaceutical Companies to face new challenges in their growth



Access to <u>trained workforce</u> for <u>R&D</u> and <u>Operations</u> activities



Consistent access to <u>utilities</u> and <u>WFI</u>



Access to Fill&Finish Capacity and Capabilities



Efficiency in manufacturing and Fill & Finish to improve Return on Investments



Proactive <u>incorporation</u> of <u>regulatory guidelines</u>





Quick industrial scale-up to **reduce** risk of **dependance** from **external sources**

How Stevanato Group can support Pharmaceutical Companies in Developing countries to overcome these challenges

Pharmaceuticals Needs for Fill & Finish



NEED TO INCREASE FLEXIBILITY



REDUCE COMPLEXITY




NEED TO INCREASE QUALITY



REDUCE TIME TO MARKET & QUICK INDUSTRIAL SCALE-UP



NEED TO REDUCE TOTAL COST OF OWNERSHIP (TCO)



- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill[®] Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish Process
- Q&A




EZ-fill® vials Platform At a Glance | Producing Significant Value for Pharma Companies



- **EZ-fill® vials** are pre-**washed**, pre-**sterilized** and **ready-to-fill** vials available in both nested and tray configurations
- No Glass-to-Glass packaging (Nest & Tub or Tray) to minimize possible scratches or other glass defects during shipment, aligned with ISO 21881
- EZ-fill® Nest & Tub configuration is compatible with multi purpose fill & finish lines
- **EZ-fill® Tray** is compatible with a wide range of fill&finish process, from **manual** to **automatic**, up to **high speed fill&finish lines**
- EZ-fill® packaging, both Tray and Nest & Tub, can be packed with either **single** or **double steribag**
 - EZ-fill® platform is an **open platform**, currently used by other primary packaging suppliers

Stevanato Group Process: from Bulk to EZ-fill®





Packaging Supplier




Shipment to Pharma Site




Strong mitigation of the risk of breakages and cosmetic issues

Filling/Inspection Operations

Ready-to-Use Secondary Packaging configurations can support a wide range of Pharmacautical Needs







• Configuration to fill vials, cartridges, syringes with a unique filling machine (combi lines)



Courtesy of Optima


EZ-fill® is suitable for filling applications from LOW to HIGH SPEED

Advantages of EZ-fill[®] Nest Mechanical Support of Glass Contrainers




Mechanical support from the bottom

- No stresses generated on glass
- Possibility of removal and re-insertion of the container on the same secondary packaging without risks or waste of product
- No particle generation due to friction




Advantages of EZ-fill® Tub Optimized Tub Dimensions

Optimized Tub to increase pallet density with low transportation and warehouse costs



Stevanato Group solution is currently validated in existing RTU filling lines

EZ-fill® Vials in Nest & Tub Secondary Packaging Configuration



with

Ready-to-Use Secondary Packaging configurations can support a wide range of Pharmacautical Needs

EZ-fill® Vial in **Tray**



- Manual filling at laboratory scale
- Industrial lines filling RTU Vials according to existing process (manual/automatic)





Courtesy of Syntegon

EZ-fill® Vial in Nest&Tub



REDUCE TIME TO MARKET & QUICK INDUSTRIAL SCALE-UP



REDUCE TOTAL COST OF OWNERSHIP (TCO)



Courtesy of Optima

Stevanato Group EZ-fill® is suitable for filling applications from LOW to HIGH SPEED


Advantages of EZ-fill® Tray Vial Different Orientations According to Filling Requirements




Neck-up Vial Solutions for Laboratory Scale




Direct filling of vials inside Tray under laminar flow




Upside-down to load in a line with conventional filling system




EZ-fill® Vials in Tray Secondary Packaging Configuration





Box composition




Pallet composition

Proven technologies available in the market to guarantee processability of EZ-fill® Vials in Fill & Finish


The technology used for the infeed of the packaging can impact the timeline and costs for the adoption of EZ-fill® vials platform





Stevanato Group can support pharmaceutical industry in both approaches, leveraging the benefits of EZ-fill® vials to reduce the risk of particles generation and human intervention

Some examples of de-traying of EZ-fill® vials





MANUAL DE-TRAYING WITH DEDICATED TOOL

SEMI-AUTOMATIC DE-TRAYING


- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill® Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish Process
- Q&A



Benefit of EZ-fill® vials Improved integrity and safety of the medicine

GLASS-TO-GLASS AND GLASS-TO-METAL CONTACT **WASHING & DEPYROGENATION** INFEED³ **DRYING* TUNNEL*** * Critical Process Steps removed from operations

FINISH




NO GLASS-TO-GLASS AND NO GLASS-TO-METAL CONTACT

Reduced risk of contamination

- Low particles contamination, lined up with the updated regulatory guidance
- Improved mechanical resistance (mitigation of glass breakage)
- **Higher process efficiency** (lower scrap rate after AVI)

Reduced risk of rejections, complaints and recalls

- Reduced risk of glass particles
- Improved cosmetic quality and reduced critical defects





INCREASE QUALITY




INCREASE FLEXIBILITY



REDUCE COMPLEXITY

Benefit of EZ-fill® vials | Fill & Finish process design to reduce footprint and improve quality


Bulk Traditional Process



- D. Rotary table/Buffer station
- E. Filling module
- F. Stoppering module
- **G.** Crimping module
- H. Visual inspection module
- I. Rejection/Recirculation
- L. Finished products

EZ-fill® Vials Benefit can be evaluated focusing on the infeed of primary packaging on the process


EZ-fill® Aseptic Process




- 1. Pass/box system
- 2-3. Debagging module
- 4. Delidding & Detraying module

Benefit of EZ-fill® vials | Reduction of risk of breakages/rejections and improved efficiency

Bulk Traditional Process



EZ-fill® Aseptic Process



- Reduction of risk of breakages and rejections given the impact of Depyrogenation on cosmetic quality.
- Potential increase in the throughput of the line by removing the complexity generated in handling washing and depyrogenation modules.



REDUCE COMPLEXITY




NEED TO INCREASE QUALITY




NEED TO REDUCE TOTAL COST OF OWNERSHIP (TCO)

Benefit of EZ-fill® vials | Reduction of Clean Room area and no need for Washing and Depyrogenation

Bulk Traditional Process



EZ-fill® Aseptic Process




- By reducing Clean Room area reduired in Grade C and Grade B and removing the need of Washing &
 Depyrogenation, it is possible to reduce initial investment as well as the time for start-up.
- Less Clean Room area and no washing and depyrogenation reduces validation activites (cost and timeline) and utilities consumption.






Benefit of EZ-fill® vials | Benefits of EZ-fill® can be evaluated also at Manufacturing site scale

Bulk Traditional Process



EZ-fill® Aseptic Process



- Depyrogenation oven impact highly the space required for Fill & Finish operations*.
- Reduction of the footprint of Fill & Finish department due to lower footprint of equipments and clean room areas.
- Reduction of the timeline for the department set-up and of the space & investments required.






Benefit of EZ-fill[®] vials | No need for Water For Injection loop for Fill & Finish equipments

Bulk Traditional Process WFI ISO 8 / Class C ISO 8 / Class C ISO 7 / Class B ISO 7 / Class B ISO 8 / Class C ISO 8 / Class C ISO 7 / Class B ISO 7 / Class B

EZ-fill® Aseptic Process




- WFI Loop and infrastructure related to Fill & Finish can be reduced.
- Reduction of WFI results in reduction of water waste, reduction of initial investment and utilities costs.
- Reduction of the timeline for the department set-up and of the space & investments required.







OWNERSHIP (TCO)

Benefit of EZ-fill® vials | No need for oven Start up in production for Fill & Finish equipments







- Avoiding depyrogenation
 oven results in reduction of
 initial investment and
 utilities costs.
- Reduction of the timeline for the department set-up and of the space & investments required.








Benefit of EZ-fill[®] vials | Same packaging configuration across different stages of Fill & Finish design

From the early stages to industrial production.



- Same Fill & Finish Equipment across from Clinical to Commercial Manufacturing
- No change on the primary packaging from Discovery to Commercial
- Same Fill & finish procedures from Clinical to Commercial Manufacturing
- Possibility to plan resources and workforce in advance before Commercial Manufacturing

- Reduced investment in Fill & Finish Equipment
- Streamline container characterization and validation activities
- Reduced training required for operators
- Reduced risk related to lack of trained workforce available




REDUCE TIME TO MARKET & QUICK INDUSTRIAL SCALE-UP



REDUCE TOTAL COST OF OWNERSHIP (TCO)

The advantages to Fill & Finish operations by EZ-fill® vials impacts positively not only on set-up time, but also on Total Cost of Ownership



Stevanato Group can support Pharma Companies in evaluating how using EZ-fill® vials configuration can reduce cost of upstream operations as well as timelines for Fill & Finish capacity with dedicated tools

Key Takeaway on EZ-fill® vials platform

EZ-fill® vials is the solution for **fasten the industrial scaled-up** for Fill&Finish solutions considering the following topics



Reduction of risk of contamination



Reduction of breakages, rejections and improved cosmetic quality



Improve the overall process effectiveness



Reduction of <u>utilities consumption</u>



Reduction of initial CAPEX



Reduce Time To Market & Quick Industrial Scale-up







- Stevanato Group at a glance
- Development Countries and Pharmaceutical Landscape
- EZ-fill[®] Vials Ready-to-Use platform
- Benefits of EZ-fill[®] Vials on Fill & Finish Process
- Q&A



We're looking forward to meeting you at DVCMN Annual Meeting – Booth 5

DCVMN Annual Meeting

19 - 21 September 2023

Cape Town - South Africa



Don't miss the opportunity to meet us during the DCVMN Annual Meeting.

Visit us at the Stevanato Group tabletop and join our corporate presentation during the conference session!

Discover how we exploit our range of **services**, **products**, and **technologies** to offer integrated solutions for the pharma and healthcare industry.



Speech:

Thursday, September 21st - 01:30 pm to 3:00 pm (SAST)

Andrea Zambon – Corporate Business Development

SESSION:

"Leveraging Innovative Platforms for Novel Vaccines"



Book a meeting with us



Thank You!